Published in Am Surg on August 01, 2010
Portosystemic Shunts: Stable Utilization and Improved Outcomes, Two Decades After the Transjugular Intrahepatic Portosystemic Shunt. J Am Coll Radiol (2015) 0.92
Clinical Management of Chronic Portal/Mesenteric Vein Thrombosis: The Surgeon's Point of View. Viszeralmedizin (2014) 0.86
Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. Clin Gastroenterol Hepatol (2011) 0.85
Transjugular intrahepatic portosystemic shunt. Clin Liver Dis (2014) 0.84
Delayed liver laceration following transjugular intrahepatic portosystemic shunt for portal hypertension. World J Gastroenterol (2012) 0.83
MRI-monitored intra-shunt local agent delivery of motexafin gadolinium: towards improving long-term patency of TIPS. PLoS One (2013) 0.77
Transjugular intrahepatic portosystemic shunt versus surgical shunting in the management of portal hypertension. Chin Med J (Engl) (2015) 0.75
Liver surgery in cirrhosis and portal hypertension. World J Gastroenterol (2016) 0.75
Transjugular intrahepatic portosystemic shunt (TIPS) versus laparoscopic splenectomy (LS) plus preoperative endoscopic varices ligation (EVL) in the treatment of recurrent variceal bleeding. Surg Endosc (2013) 0.75
Surgical portosystemic shunts in the era of TIPS and liver transplantation are still relevant. HPB (Oxford) (2013) 0.75
General surgery residency inadequately prepares trainees for fellowship: results of a survey of fellowship program directors. Ann Surg (2013) 4.29
Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg (2009) 2.33
Student quality-of-life declines during third year surgical clerkship. J Surg Res (2007) 2.05
The use of virtual patients to teach medical students history taking and communication skills. Am J Surg (2006) 1.84
Laparoendoscopic single site cholecystectomy: the first 100 patients. Am Surg (2009) 1.72
Laparoendoscopic single site (LESS) cholecystectomy. J Gastrointest Surg (2008) 1.66
Does Barrett's esophagus impact outcome after laparoscopic Nissen fundoplication? Am J Surg (2006) 1.44
Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol (2002) 1.27
Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol (2006) 1.23
Symptoms and antireflux medication use following laparoscopic Nissen fundoplication: outcome at 1 and 4 years. JSLS (2003) 1.21
Laparoscopic Heller myotomy provides durable relief from achalasia and salvages failures after botox or dilation. Ann Surg (2005) 1.09
CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg (2008) 1.08
TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res (2002) 1.08
Surgical management of early-stage pancreatic cancer. Cancer Control (2004) 1.07
Public perception of LESS surgery and NOTES. J Gastrointest Surg (2011) 1.05
Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res (2006) 1.05
Patients' perceptions of laparoendoscopic single-site surgery: the cosmetic effect. Am J Surg (2012) 1.05
Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg (2003) 1.04
The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg (2010) 1.02
An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol (2008) 1.02
Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg (2005) 0.99
Gene expression profiling of colorectal mucinous adenocarcinomas. Dis Colon Rectum (2010) 0.99
A single institution's experience with more than 500 laparoscopic Heller myotomies for achalasia. J Am Coll Surg (2010) 0.99
Twenty-millimeter laparoscopic cholecystectomy: fewer ports results in less pain, shorter hospitalization, and faster recovery. Am Surg (2005) 0.98
Frequency with which surgeons undertake pancreaticoduodenectomy continues to determine length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg (2007) 0.96
Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg (2002) 0.94
Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) (2012) 0.93
Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies. Ann Surg Oncol (2004) 0.93
Early results of laparoscopic Heller myotomy do not necessarily predict long-term outcome. Am J Surg (2004) 0.92
Ictal EEG remains the prominent predictor of seizure-free outcome after temporal lobectomy in epileptic patients with normal brain MRI. Seizure (2008) 0.91
Selective application of fundoplication during laparoscopic heller myotomy ensures favorable outcomes. Surg Laparosc Endosc Percutan Tech (2002) 0.90
The "learning curve" in videoscopic Heller myotomy. JSLS (2002) 0.90
Consensus statement of the consortium for LESS cholecystectomy. Surg Endosc (2012) 0.90
Resection of portovenous structures to obtain microscopically negative margins during pancreaticoduodenectomy for pancreatic adenocarcinoma is worthwhile. Am Surg (2009) 0.90
Esophagotomy during laparoscopic Heller myotomy cannot be predicted by preoperative therapies and does not influence long-term outcome. J Gastrointest Surg (2005) 0.89
Transduodenal ampullectomy for ampullary adenomas: a safe and effective procedure with long-term salutary outcomes. Am Surg (2014) 0.89
Videoscopic Heller myotomy with intraoperative endoscopy promotes optimal outcomes. JSLS (2002) 0.89
A single institution's experience and journey with over 1000 laparoscopic fundoplications for gastroesophageal reflux disease. Am Surg (2012) 0.88
Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial. J Am Coll Surg (2012) 0.88
Realistic expectations and leadership in the era of work hour reform. J Surg Res (2005) 0.88
Reproductive factors and risk of pancreatic cancer in women: a review of the literature. Ann Epidemiol (2009) 0.88
Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. HPB (Oxford) (2011) 0.88
Preoperative intervention does not affect esophageal muscle histology or patient outcomes in patients undergoing laparoscopic Heller myotomy. J Gastrointest Surg (2003) 0.87
Defining the learning curve of laparoendoscopic single-site Heller myotomy. Am Surg (2013) 0.87
Age affects presenting symptoms of achalasia and outcomes after myotomy. Am Surg (2005) 0.87
Ten-year follow up after laparoscopic Nissen fundoplication for gastroesophageal reflux disease. Am Surg (2007) 0.87
Laparoscopic Nissen fundoplication offers high patient satisfaction with relief of extraesophageal symptoms of gastroesophageal reflux disease. Am Surg (2006) 0.87
Perspectives of third-year medical students toward their surgical clerkship and a surgical career. J Surg Res (2007) 0.86
Laparoendoscopic single-site Heller myotomy with anterior fundoplication for achalasia. Surg Endosc (2011) 0.85
Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts? Am J Surg (2011) 0.85
Difficult myotomy is not determined by preoperative therapy and does not impact outcome. JSLS (2007) 0.84
Laparoscopic Heller myotomy for achalasia: results after 10 years. Surg Endosc (2009) 0.84
Outpatient case management in low-income epilepsy patients. Epilepsy Res (2008) 0.83
Surgeons can favorably influence career choices and goals for students interested in careers in medicine. J Am Coll Surg (2009) 0.83
EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J Surg Res (2006) 0.83
Laparo-endoscopic single-site (LESS) cholecystectomy with epidural vs. general anesthesia. Surg Endosc (2012) 0.82
In-continuity hepatic resection for advanced hilar cholangiocarcinoma. Am J Surg (2004) 0.82
Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg (2004) 0.82
Access for laparoendoscopic single site surgery. Diagn Ther Endosc (2010) 0.82
Does concomitant anterior fundoplication promote dysphagia after laparoscopic Heller myotomy? Am Surg (2008) 0.81
TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am J Surg (2005) 0.81
Pancreatic adenocarcinoma: complete tumor extirpation improves survival benefit despite larger tumors for patients who undergo distal pancreatectomy and splenectomy. J Gastrointest Surg (2011) 0.81
A Single Institution's First 100 Patients Undergoing Laparoscopic Anti-Reflux Fundoplications: Where Are They 20 Years Later? Am Surg (2015) 0.81
Laparoscopic resection of extraadrenal pheochromocytoma. Ann Surg Oncol (2007) 0.80
Readmissions after pancreaticoduodenectomy: efforts need to focus on patient expectations and nonhospital medical care. Am Surg (2012) 0.80
Obesity is not a contraindication to laparoscopic Nissen fundoplication. J Gastrointest Surg (2005) 0.80
Laparoscopic Nissen fundoplication ameliorates symptoms of reflux, especially for patients with very abnormal DeMeester scores. Am Surg (2008) 0.80
Laparoscopic Heller myotomy with anterior fundoplication ameliorates symptoms of achalasia in pediatric patients. J Am Coll Surg (2007) 0.80
Esophagography predicts favorable outcomes after laparoscopic Nissen fundoplication for patients with esophageal dysmotility. J Am Coll Surg (2005) 0.80
Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol (2006) 0.80
Gastroesophageal reflux disease. Surg Clin North Am (2011) 0.80
Causes of dissatisfaction after laparoscopic fundoplication: the impact of new symptoms, recurrent symptoms, and the patient experience. Surg Endosc (2013) 0.80
Transoral incisionless fundoplication: is it as safe and efficacious as a Nissen or Toupet fundoplication? Am Surg (2014) 0.79
Targeting early deaths following pancreaticoduodenectomy to improve survival. J Gastrointest Surg (2012) 0.78